Inhibrxの評価平均
Inhibrxの評価平均は何ですか。
Inhibrx, Inc.の評価平均は1.80です。
評価平均の定義は何ですか。
Recommendation meanは、株式のアナリストの格付けの平均値で、1.0（強い買い）から5.0（強い売り）の範囲です。
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
NASDAQのセクタHealth Careにおける評価平均の企業と比べるInhibrx
Inhibrxは何をしますか。
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Inhibrxと類似の評価平均
- Linde Plcの評価平均は1.79です。
- Quest Diagnosticsの評価平均は1.79です。
- Skyworks Solutionsの評価平均は1.79です。
- DocuSign Incの評価平均は1.79です。
- Monster Beverageの評価平均は1.79です。
- Digital Realty Trust Incの評価平均は1.79です。
- Inhibrxの評価平均は1.80です。
- Darden Restaurantsの評価平均は1.81です。
- Brunswickの評価平均は1.81です。
- Revolve Incの評価平均は1.81です。
- Targa Resources Corpの評価平均は1.81です。
- Astrazeneca plcの評価平均は1.81です。
- Planet Fitness Incの評価平均は1.81です。